Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 7/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL662828 | 1.00 | CLK1 (0.42) | CLK1UTS2RDGAT1CLK2CHRNA7 | |
| SCHEMBL662829 | 1.00 | CLK1 (0.42) | CLK1UTS2RDGAT1CLK2CHRNA7 | |
| SCHEMBL10184525 | 0.93 | DGAT1 (0.40) | CLK1UTS2RDGAT1CLK2CHRNA7 | |
| SCHEMBL10186265 | 0.91 | UTS2R (0.41) | CLK1UTS2RDGAT1CLK2CHRNA7 | |
| SCHEMBL10185434 | 0.90 | RAB9A (0.44) | CLK1DGAT1HRH3 | |
| SCHEMBL10186287 | 0.89 | UTS2R (0.43) | CLK1UTS2RDGAT1CLK2CHRNA7 | |
| SCHEMBL10185623 | 0.88 | DGAT1 (0.51) | CLK1UTS2RDGAT1CHRNA7HTR3A | |
| SCHEMBL10185723 | 0.88 | UTS2R (0.45) | CLK1UTS2RDGAT1CLK2CHRNA7 | |
| SCHEMBL10186508 | 0.87 | UTS2R (0.48) | CLK1UTS2RDGAT1CLK2CHRNA7 | |
| SCHEMBL10185104 | 0.86 | PRSS12 (0.44) | UTS2RDGAT1CHRNA7HRH3SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | CLK1 2402/4885UTS2R 2678/4885DGAT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.